Alumis (ALMS) Stock News

Alumis (Nasdaq: ALMS) reported third quarter 2025 results and program milestones on Nov 13, 2025. Cash, cash equivalents and marketable securities were $377.7 million as of Sept 30, 2025, which the company expects will fund operations into 2027. Revenue for the quarter included $2.1 million of collaboration revenue. R&D expense was $97.8 million and G&A was $19.5 million for Q3 2025; net loss was $110.8 million. Key clinical milestones: topline Phase 3 ONWARD envudeucitinib (PsO) data expected early Q1 2026 and Phase 2b LUMUS (SLE) topline in Q3 2026; A-005 Phase 2 MS start planned H1 2026.

Alumis (Nasdaq: ALMS) will participate in two investor conferences in November 2025: Guggenheim Healthcare Innovation Conference in Boston (Nov 10-12) with a fireside chat on Nov 11, 2025 at 1:30 PM ET, and the Stifel 2025 Healthcare Conference in New York (Nov 11-13) with a presentation on Nov 12, 2025 at 2:00 PM ET.

Live webcasts will be available via the company’s Investors > Events page, and replay archives will remain on the website for 90 days.

Alumis (Nasdaq: ALMS), a late-stage biopharma company focused on immune-mediated disease therapies, has announced its participation in six major investor conferences during September 2025. The company will present at the Cantor Global Healthcare Conference, Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Baird Global Healthcare Conference, and Stifel Virtual Immunology & Inflammation Forum.

All presentations will be accessible via webcast through Alumis's investor relations website, with replays available for 90 days following each event.

Alumis (Nasdaq: ALMS) reported Q2 2025 financial results and significant clinical progress. The company completed enrollment in two major trials: the Phase 3 ONWARD trials for envudeucitinib in plaque psoriasis (topline data expected Q1 2026) and the Phase 2b LUMUS trial for systemic lupus erythematosus (topline data expected Q3 2026).

Key financial highlights include $486.3 million in cash and equivalents, expected to fund operations into 2027. Q2 revenue was $2.7 million from the Kaken Pharmaceutical collaboration. The company reported a net income of $59.3 million, including a $187.9 million gain from the ACELYRIN merger.

R&D expenses increased to $108.8 million (vs $48.6M in Q2 2024), while G&A expenses rose to $34.5 million (vs $7.6M in Q2 2024). The merger with ACELYRIN added $382.6 million to the company's cash position.

Alumis (Nasdaq: ALMS) has completed patient enrollment in its global LUMUS Phase 2b trial for ESK-001, a next-generation oral TYK2 inhibitor targeting systemic lupus erythematosus (SLE). The trial has enrolled 408 patients who will receive ESK-001 or placebo for 48 weeks.

The study will evaluate the drug's efficacy in treating moderately-to-severely active, autoantibody-positive SLE, with topline data expected in Q3 2026. The primary endpoint will measure disease activity improvements using the BICLA assessment at Week 48. The company reports that ESK-001 has shown promising results in their psoriasis program, demonstrating full target inhibition and general tolerability.

Alumis (Nasdaq: ALMS), a late-stage biopharma company focused on immune-mediated diseases, has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary. Pangali, who previously served as Senior Vice President, Legal at Alumis, succeeds Sara Klein following her retirement.

In her new role, Pangali will oversee all legal and compliance functions, including corporate governance, intellectual property, and strategic advisory. She brings significant experience from her previous positions at ACELYRIN, Snapdocs, and Principia Biopharma, where she held senior legal roles. Her background includes leading legal affairs through significant corporate events, including IPOs and mergers.

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company focused on developing next-generation targeted therapies for immune-mediated diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO, Martin Babler, will deliver a presentation on June 4, 2025, at 3:10 p.m. ET. Interested parties can access a live webcast of the presentation through the "Investors" section of the Alumis website, under the "Events" page. The webcast recording will remain available for replay on the company's website for 90 days following the event.

Alumis Inc. (ALMS) has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program evaluating ESK-001, a next-generation oral TYK2 inhibitor, for treating moderate-to-severe plaque psoriasis. The program includes two parallel Phase 3 trials with over 1,700 patients enrolled, with topline results expected in early Q1 2026. ESK-001 aims to address current treatment challenges by offering a well-tolerated oral alternative to injectable biologics, potentially delivering durable, biologic-like clinical responses. The ONWARD program consists of ONWARD1 and ONWARD2 (24-week trials), plus ONWARD3, an optional long-term extension trial to assess durability and safety.

Alumis Inc. (NASDAQ: ALMS) has completed its merger with ACELYRIN, Inc., creating a leading clinical-stage biopharma company focused on immune-mediated diseases. Under the merger terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each ACELYRIN share. ACELYRIN's stock has been delisted from NASDAQ.

The merger significantly strengthens Alumis' balance sheet, extending its cash runway into 2027. The combined company aims to advance its late-stage portfolio through multiple planned key data readouts. Morgan Stanley advised Alumis, while Guggenheim Securities advised ACELYRIN in the transaction.